Sector revisions Genmab A/S

Equities

Delayed Nasdaq Copenhagen Other stock markets 11:20:00 2026-05-13 EDT			5-day change	1st Jan Change
1,684.00 ^DKK	-1.66%		-4.83%	-16.92%

05-12	Nordea resumes coverage of Genmab with Buy rating and DKK 2,015 price target	FW
05-11	Deutsche Bank trims Genmab price target to DKK 2,250 (2,400), reiterates Buy	FW

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
GENMAB A/S				15
ARGENX SE				15
WUXI APPTEC CO., LTD.				17
INSMED INCORPORATED				20
BIONTECH SE				18
WUXI BIOLOGICS (CAYMAN) INC.				21
AKESO, INC.				21
SUMMIT THERAPEUTICS INC.				14
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				17
EXELIXIS, INC.				17
MADRIGAL PHARMACEUTICALS, INC.				14
ARROWHEAD PHARMACEUTICALS, INC.				12
CYTOKINETICS, INCORPORATED				19
REMEGEN CO., LTD.				15
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	-	1
IMMUNITYBIO, INC.				4
PHARMAESSENTIA CORPORATION				6
NUVALENT, INC.				18
VAXCYTE, INC.				9
Average				14
Weighted average by Cap.				16